Stopping expensive biological drugs used to treat rheumatoid arthritis in patients who are in remission or who have low disease activity can save considerable costs, but it results in a small loss of quality-adjusted life years.

‘Stopping expensive biological drugs used to treat rheumatoid arthritis in patients who are in remission or who have low disease activity can save considerable costs, but it results in a small loss of quality-adjusted life years.’

Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints and the surrounding tissues. It is an autoimmune disease.





Source-Eurekalert